IPR3011 is a small-molecule uPAR-uPA protein-protein interaction inhibitor with Ki of 2.4 uM.

VU534 is a small molecule activator of N-acyl-phosphatidylethanolamine hydrolyzing phospholipase D (NAPE-PLD) with EC50 of 0.3 uM, enhances efferocytosis by macrophages.

VU533 is a small molecule activator of N-acyl-phosphatidylethanolamine hydrolyzing phospholipase D (NAPE-PLD) with EC50 of 0.3 uM, enhances efferocytosis by macrophages.

KT-203 (KT203) is a potent, selective inhibitor of α/β-hydrolase domain 6 (ABHD6) with IC50 of 3.9 nM in 2-AG hydrolysis assays.

ABD298 is a potent, selective ABHD13 inhibitor, inhibits HEK293T cells expressing recombinant mouse ABHD13 with IC50 of 0.98 uM.

Yonkenafil is a potent, selective PDE5 inhibitor with IC50 of 2.0 nM.

TPN171 (TPN-171) is a highly potent, selective phosphodiesterase type 5 (PDE5) inhibitor with IC50 of 0.62 nM, 32-fold selectivity over PDE6.

TOP-N53 is a dual-acting nitric oxide (NO) donor and selective PDE5 inhibitor, potently inhibits PDE5 with IC50 of 1.6 nM.

A potent and selective PDE10A inhibitor with IC50 of 0.37 nM.

ME3183 is a potent, selective phosphodiesterase 4 (PDE4) inhibitor with IC50 of 2.33, 1.28 and 1.63 nM for PDE4B1, PDE4A1A and PDE4D2 respectively.

MCI-030 (ADT 061) is a potent, selective PDE10 inhibitor, inhibits recombinant PDE10 using cGMP as a substrate with IC50 of 0.3 uM.

Gemlapodect (NOE-105) is a potent, selective PDE10A inhibitor with a potential therapeutic effect for the treatment of COFD.

MM201 is a novel potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with IC50 of 74.3 nM in in vitro biochemical assays.

A4276 is a novel orally bioavailable NAMPT inhibitor with IC50 of 492 nM for inhibiting NAMPT enzymatic activity, shows high selectivity for NAPRT-deficient lung cancer cell lines.

TIPTP is a highly potent and selective inhibitor of p22phox, inhibits the p22phox-Rubicon interaction with IC50 of 0.1 uM, and suppresses ROS-mediated inflammation.

LMH001 is a small chemical compound blocking phosphorylated p47phox interaction with p22phox, inhibits effectively angiotensin II (AngII)-induced endothelial Nox2 activation and superoxide production (IC50=0.25 uM).

GLX481304 is a specific small molecule inhibitor of Nox2 and Nox4 with IC50 values of 1.25 uM, shows negligible effects on Nox1.

AKU-005 is a potent, dual MAGL/FAAH inhibitor with IC50 of 589 and 309 pM for MAGL in rat and mouse brain membrane respectively, inhibits rat and human FAAH with IC50 of 63 and 389 nM.

TP0628103 is a highly potent, selective matrix metalloproteinase-7 (MMP-7) inhibitor with IC50 of 0.17 nM and 4.1 nM for human and mouse MMP-7, respectively.

TAPI-0 is a potent, selective inhibitor of TNFalpha converting enzyme (TACE, ADAM7) with IC50 of 100 nM.

MMP408 (MMP 408) is a potent, selective matrix metalloprotease 12 (MMP-12) inhibitor with IC50 of 2.0 nM (human MMP-12), 60-fold selectivity over MMP-13.

MMP118 is a potent, selective and orally bioavailable matrix metalloproteinase-12 (MMP-12) inhibitor with IC50 of 1.0 nM (hMMP-12), 1980- and 154-fold selectivity over MMP-13 and MMP-8 respectively.

JTP-96193 (JTP96193) is a potent, selective TNF-α converting enzyme (TACE/ADAM17) inhibitor with IC50 of 5.4 nM, >1800-fold selectivity against ADAM10.

IPR-179 (ACT-03) is a potent, BBB-permeable, selective gelatinase (MMP2 and MMP9) inhibitor with IC50 of 656 nM and 310 nM, respectively.

CID 3117694 is a selective, non-competitive inhibitor of ADAM10 with IC50 of 1.1 uM, does not inhibit ADAM17.

AZD1236 is a potent, selective MMP-9 and MMP-12 inhibitor with IC50 of 4.5 and 6.1 nM respectively, >10-fold selectivity to MMP-2 and MMP-13 and >350-fold selectivity to other MMPs.

SRK2128 (SRK 2128) is a highly potent HMG-CoA reductase degrader with EC50 of 84 nM, potently induce degradation of HMG-CoA reductase.

TMG-123 (TMG123) is a potent small molecule activator of glucokinase (GK) with EC50 of 0.35 and 0.32 uM for human liver and pancreas GK, respectively.

GKM-001 is a potent, liver-selective small molecule activator of glucokinase (GKA), demonstrates glucose lowering effect without hypoglycemia in normal and type II diabetes mellitus (T2DM).

GKA23 is a potent, small molecule glucokinase (GK) activator with EC50 of 152 nM for glucokinase activation in 5 mM glucose, increases glucose uptake in primary rat hepatocytes with EC50 of 201 nM.